Talk:Transcription activator-like effector nuclease

Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent.

This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Molecular Biology: MCB This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles ??? This article has not yet received a rating on the importance scale. This article is supported by the Molecular and Cell Biology task force (assessed as Mid-importance).

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE. Dcbennett2 (talk · contribs) has been paid by SciWri Services on behalf of Cellectis. Their editing has included contributions to this article. Paid editing declared here

This article could be improved by adding a section on the history of the discovery of TALENs. Biolprof (talk) 21:43, 22 January 2014 (UTC)[reply]

This article was the subject of a Wiki Education Foundation-supported course assignment, between 31 January 2022 and 22 May 2022. Further details are available on the course page. Student editor(s): Saucyscience (article contribs).

Or is that too detailed? The relevant paper is already submitted as a source. Patwis (talk) 11:15, 25 May 2022 (UTC)[reply]

"gRNAs have occasionally limitations regarding feasibility due to lack of PAM sites in the target sequence and even though they can be cheaply produced, the current development lead to a remarkable decrease of cost for TALENs, so that they are in a similar price and time range like CRISPR based genome editing" 162.249.205.250 (talk) 22:38, 24 April 2023 (UTC)[reply]